Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Three-month treatment with pioglitazone reduces circulating C1q-binding adiponectin complex to total-adiponectin ratio, without changes in body mass index, in people with type 2 diabetes.

Nakatsuji H, Kishida K, Kobayashi H, Funahashi T, Shimomura I; Senri Study II Group.

Diabetes Res Clin Pract. 2013 Jan;99(1):e14-7. doi: 10.1016/j.diabres.2012.10.003. Epub 2012 Nov 9.

PMID:
23142017
2.

Withdrawal of pioglitazone in patients with type 2 diabetes mellitus.

Iwase M, Asano T, Sasaki N, Yoshizumi H, Hiramatsu S, Sakai Y, Ogo A, Iida M.

J Clin Pharm Ther. 2010 Aug;35(4):401-8. doi: 10.1111/j.1365-2710.2009.01109.x.

PMID:
20831543
3.

Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetes.

Nakatsuji H, Kishida K, Funahashi T, Shimomura I; Senri Study II Group.

Atherosclerosis. 2010 Sep;212(1):243-5. doi: 10.1016/j.atherosclerosis.2010.05.025. Epub 2010 May 24. No abstract available.

PMID:
20541758
4.

Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes.

Ochiai H, Ooka H, Shida C, Ishikawa T, Inoue D, Okazaki R.

Endocr J. 2008 Jul;55(3):549-56. Epub 2008 May 15.

5.

High serum C1q-adiponectin/total adiponectin ratio correlates with coronary artery disease in Japanese type 2 diabetics.

Hirata A, Kishida K, Nakatsuji H, Kobayashi H, Funahashi T, Shimomura I.

Metabolism. 2013 Apr;62(4):578-85. doi: 10.1016/j.metabol.2012.10.011. Epub 2012 Nov 20.

PMID:
23174407
6.

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M.

Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9.

7.

Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes.

Aso Y, Hara K, Ozeki N, Yatsuka C, Nakano T, Matsumoto S, Suetsugu M, Nakamachi T, Takebayashi K, Haruki K, Inukai T.

Diabetes Res Clin Pract. 2009 Aug;85(2):147-52. doi: 10.1016/j.diabres.2009.05.015. Epub 2009 Jun 21.

PMID:
19545925
8.

Correlation between serum C1q-adiponectin/total adiponectin ratio and polyvascular lesions detected by vascular ultrasonography in Japanese type 2 diabetics.

Hirata A, Kishida K, Kobayashi H, Nakatsuji H, Funahashi T, Shimomura I.

Metabolism. 2013 Mar;62(3):376-85. doi: 10.1016/j.metabol.2012.08.009. Epub 2012 Oct 9.

PMID:
23058931
9.

The ratio of leptin to adiponectin can be used as an index of insulin resistance.

Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, Itoh M.

Metabolism. 2008 Feb;57(2):268-73. doi: 10.1016/j.metabol.2007.09.011.

PMID:
18191059
10.

Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.

Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P.

Clin Endocrinol (Oxf). 2006 Dec;65(6):722-8.

PMID:
17121522
11.

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T.

Metabolism. 2002 Mar;51(3):314-7.

PMID:
11887166
12.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
13.

Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.

Oz O, Tuncel E, Eryilmaz S, Fazlioglu M, Gul CB, Ersoy C, Ocak N, Dirican M, Cangur S, Baran I, Imamoglu S.

Endocrine. 2008 Feb;33(1):101-5. doi: 10.1007/s12020-008-9058-x. Epub 2008 Apr 5.

PMID:
18392690
14.

Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity.

Nakatsuji H, Kishida K, Funahashi T, Shimomura I; Senri Study II Group.

Diabetes Res Clin Pract. 2012 Mar;95(3):e58-60. doi: 10.1016/j.diabres.2011.11.018. Epub 2011 Dec 9.

PMID:
22154375
15.

Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.

Aso Y, Yamamoto R, Suetsugu M, Matsumoto S, Wakabayashi S, Matsutomo R, Takebayashi K, Inukai T.

Diabet Med. 2007 Sep;24(9):962-8. Epub 2007 May 17.

PMID:
17509067
16.

Binding of adiponectin and C1q in human serum, and clinical significance of the measurement of C1q-adiponectin / total adiponectin ratio.

Nakatsuji H, Kobayashi H, Kishida K, Nakagawa T, Takahashi S, Tanaka H, Akamatsu S, Funahashi T, Shimomura I.

Metabolism. 2013 Jan;62(1):109-20. doi: 10.1016/j.metabol.2012.06.006. Epub 2012 Jul 21.

PMID:
22819529
17.

Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes.

Maegawa H, Nishio Y, Nakao K, Ugi S, Maeda K, Uzu T, Kashiwagi A.

Endocr J. 2007 Aug;54(4):613-8. Epub 2007 Jul 20.

18.

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.

Forst T, Hohberg C, Fuellert SD, Lübben G, Konrad T, Löbig M, Weber MM, Sachara C, Gottschall V, Pfützner A.

Horm Metab Res. 2005 Aug;37(8):521-7.

PMID:
16138267
19.

Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease.

Patel SR, Mailloux LM, Coppola JT, Mindrescu C, Staniloae CS.

Coron Artery Dis. 2008 Aug;19(5):349-53. doi: 10.1097/MCA.0b013e3282fd5c37.

PMID:
18580598
20.

Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.

Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M.

Metabolism. 2007 Oct;56(10):1418-24.

PMID:
17884455

Supplemental Content

Support Center